Ken Nelson currently serves as a partner in the Medtech Advantage Fund, which has an exclusive partnership with Medtech Innovator (www.medtechinnovator.org ), the largest MedTech and Digital Health startup accelerator globally. In addition, he serves as Chairman of the Board for CardiaCare and is an active board member for HeartX, HeartBeam (NASDAQ: BEAT), Happitech, and a handful of other disruptive cardiac Digital Health and MedTech startups.
Over the past 10 years, Ken has led commercial efforts for disruptive technologies in the digital health, wearables, and cardiac remote patient monitoring industries, playing a significant role in building the teams, cultures, and infrastructures for 3 of the top 4 market share players in cardiac digital health and remote patient monitoring, including #1 (BioTelemetry as VP of Sales), #2 (iRhythm as VP of Sales & Marketing), and #4 (Bardy Diagnostics as Chief Commercial Officer). Most recently, he served as Head of Digital Health, Diagnostics, and Monitoring for Biotronik, a leading cardiac digital health and medical device company.
Overall, he is a 20-year digital health, medical device, and remote patient monitoring executive and innovator with successful senior leadership experience ranging from a Fortune 500 company (Boston Scientific) to a #1 market share leading medium-sized company (Biotelemetry, acquisition by Philips for $2.8 Billion announced in December ’20) to 3 start-ups, 1 of which eventually led to an extremely successful IPO (iRhythm) and another which was just acquired by HillRom/ Baxter (Bardy Diagnostics) in August 2021 for $400M+ after milestone payments.
Ken earned a B.A. in Economics from Vanderbilt University, is a graduate of Phillips Exeter Academy, and resides in Dallas, TX with his wife and 3 children.
Menu
